Clozapine Plus Lamotrigine in Treatment-Resistant Schizophrenia
The DOI matches its Crossref record.
Abstract
C lozapine is the only antipsychotic agent with proven efficacy in treatment-resistant schizophrenia; however, a substantial minority of patients fail to respond or have only a partial response to clozapine, leading clinicians to search for potential augmentation strategies to improve outcomes. To date, these augmentation strategies with clozapine have generally been disappointing. Glutamate is an excitatory neurotransmitter, and clozapine acts as a glutamate antagonist. Lamotrigine, an anticonvulsant and mood stabilizer, inhibits excessive release of glutamate. Both drugs block the psychotomimetic effects of phencyclidine (PCP). These schizophrenia-like symptoms are attributed to PCP’s activity at the NMDA (glutamate) receptor. The biochemical significance of these glutamate interactions in schizophrenia remains unclear and is hotly debated. There is evidence to suggest that there is abnormal glutamatergic binding in the areas of the brain associated with psychotic symptoms in patients with schizophrenia. We are reporting on a small, open-label, nonrandomized case series of 6 outpatients who had a partial response to clozapine. All patients were taking the maximum tolerated dose of clozapine, with lamotrigine added as an augmentation strategy. Clozapine dosages were stable at the time lamotrigine therapy was initiated and remained the same throughout the 24-week period monitored by the Brief Psychiatric Rating Scale. No patient dropped out of the study. All patients had therapeutic plasma clozapine levels and had been taking clozapine for a minimum of 16 months. Lamotrigine therapy was initiated at 12.5 mg/d and titrated by patient response. When baseline Brief Psychiatric Rating Scale scores were compared with scores in each subsequent week using a pairwise approach for the sample, all were found to be significantly different (P#.05) by Wilcoxon signed rank test (Table). Reported side effects included headache, sedation, dizziness, and mild hand tremor. No dermatological side effects were observed, and none of the side effects were considered disturbing by the patients. Despite the significant limitations of a small sample size and open-label, nonrandomized design, the preliminary data suggest that clozapine plus lamotrigine may be a useful augmentation for treatment-resistant schizophrenia. Clozapine is metabolized primarily through the liver CYP450 system (isoenzyme 1A2), while lamotrigine is metabolized in the liver by glucuronidation. Therefore, any synergism between the 2 is very likely pharmacodynamic (perhaps involving glutamate and/or nitric oxide) rather than the result of a pharmacokinetic interaction. We believe this finding warrants further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glutamate and dopamine in schizophrenia: An update for the 21 st century
Howes, O., McCutcheon, R., & Stone, J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114563634 · Cited by 702
“Early clinical data suggesting a benefit in partial responders to clozapine treatment (Dursun et al., 1999) has received subsequent support in a meta-analysis, although effects were relatively modest (Tiihonen et al.”
ResultHasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
“Preliminary clinical evidence suggests that lamotrigine may augment antipsychotic efficacy in some patients diagnosed with schizophrenia (Durson et al. 1999; Dursun and Deakin 2001; Saba et al. 2002; Tiihonen et al. 2003), and definitive research is needed to establish the benefits and risks…”
BackgroundGlutamate as a therapeutic target in psychiatric disorders
Javitt, D. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001551 · Cited by 524
Barnes, T. R., & the Schizophrenia Consensus Group of the British Association for Psychopharmacology (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110391123 · Cited by 356
Management of treatment resistance in schizophrenia
Conley, R. R., & Kelly, D. L. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01271-9 · Cited by 352
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guide, Falkai, P., Wobrock, T., Lieberman, J., et al. (2006) · The World Journal of Biological Psychiatry · doi:10.1080/15622970500483177 · Cited by 331
Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Möller, H.-J., WFSBP Task Force on Treatment Guidelines for Schizophrenia, Falkai, P., Wobrock, T., Lieberman, J., et al. (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 269
Tiihonen, J., Wahlbeck, K., & Kiviniemi, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.01.002 · Cited by 194
“In two previous open trials, lamotrigine in combination with clozapine was observed to be effective in reducing symptoms among patients with schizophrenia (Dursun et al., 1999; Dursun andDeakin, 2001).”
BackgroundChouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
The potential role of lamotrigine in schizophrenia
Large, C. H., Webster, E. L., & Goff, D. C. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0020-9 · Cited by 69
Metadata
- Authors
- Dursun, S. M., McIntosh, D., & Milliken, H.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 1999-10-01
- Volume
- 56
- Issue
- 10
- Pages
- 950
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2081824154
- Cited by
- 96
- References
- 0
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.